Ibex Medical Analytics (Ibex), a provider in AI-powered cancer diagnostics, and PathPresenter, a global image sharing platform for pathology, announced a partnership to advance the adoption of AI-powered digital pathology. 

The two companies say they will work together to support joint customers via an AI-powered digital pathology solution for laboratories, hospitals, and health systems worldwide.

“The digital pathology and AI transformation that Ibex and PathPresenter are championing is modernizing the industry and providing pathologists with AI tools to improve diagnostic accuracy, lab efficiencies and patient outcomes,” says Joseph Mossel, CEO and co-founder of Ibex Medical Analytics. “This partnership allows us to expand access to Galen, Ibex’s AI platform, to PathPresenter’s impressive community of medical institutions around the world.” 

PathPresenter is a scalable multi-tenant enterprise workflow platform featuring a comprehensive suite available for clinical care, remote consultations, education, and research. The solution provides expert guidance in storage optimization, tight integration with LIS systems through a proprietary HL7 engine, and robust incorporation of 3rd party and in-house-built AI algorithms.

“We are committed to working with the best partners to advance digital pathology adoption and education, and Ibex is a clear leader in AI-powered diagnostics,” says Rajendra Singh, MD, founder of PathPresenter. “PathPresenter is building the much-needed ‘roads and bridges’ to connect the world’s pathologists, institutions, and pharma companies to easily share image data, AI algorithms, and domain expertise. Our deep knowledge of the digital pathology workflows is complemented well by Ibex’s clinically validated AI tools, enabling pathologists to benefit from a holistic diagnostic experience.”

Further reading: Ibex Launches Galen Breast HER2 to Support Breast Cancer Biomarker Scoring

Ibex’s Galen AI-based pathology platform has been deployed in laboratories and pathology departments around the world. Galen supports clinicians worldwide with augmented capabilities during diagnosis of breast, prostate, and gastric biopsies. Improving diagnostic accuracy, reducing turnaround time, optimizing lab workflows and improving user experience for pathologists, Galen has demonstrated excellent outcomes across multiple clinical studies performed in different pathology labs and diagnostic workflows, the company says.1,2,3,4,5

References: 

  1. Sandbank et al., Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies, npj Breast Cancer, December 2022 
  2. Pantanowitz et al., An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study, THE LANCET Digital Health Aug 2020
  3. Comperat et al., Clinical Level AI-Based Solution for Primary Diagnosis and Reporting of Prostate Biopsies in Routine Use: A Prospective Reader Study, European Congress of Pathology 2021
  4. Raoux et al., Novel AI-Based Solution for Supporting Primary Diagnosis of Prostate Cancer Increases the Accuracy and Efficiency of Reporting in Clinical Routine, USCAP 2021
  5. Sandbank et al., Validation and Clinical Deployment of an AI-Based Solution for Detection of Gastric Adenocarcinoma and Helicobacter pylori in Gastric Biopsies, USCAP 2022